Role of 20-HETE in diabetic cardiovascular complications

Abstract

Abstract: Diabetes is a metabolic disorder syndrome characterized by hyperglycemia and cardiovascular complications are major causes of death and disability. 20-hydroxyeicosatetraenoic acid (20-HETE) is the newly-identified active metabolite of arachidonic acid (AA) catalyzed by cytochrome P-450 (CYP450), which is called as the third metabolic pathway of AA. Recent researches suggest its significant role in the regulation of renal function and vascular smooth muscle tension. But there is few reports about the relationship of 20-HETE and diabetes. The present article reviewed the international researches on 20-HETE and diabetic cardiovascular complications published in recent years.

Key words: 20-HETE, Diabetes, Vascular smooth muscle cells, Endothelial cells, Kidney, Hypertension

CLC Number:

LV Hong-le, FU Ping, LI Hua. Role of 20-HETE in diabetic cardiovascular complications[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 950-953.

References

[1] Benter IF,Yousif MH, Canatana H. Inhibition of Ca²⁺/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery[J].Pharmacol Res,2005,52(3):252-257.
[2] Yousif MH, Benter IF, Dunn KM, et al. Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes[J]. Auton Autacoid Pharmacol,2009,29(1/2):1-12.
[3] Andreas S,Paolo G,Daniela F,et al. Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction rescue by guanylyl-cyclase activation[J]. Diabetes,2010,59(8):2001-2009.
[4] Ward NC, Rivera J, Hodgson J, et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans[J]. Circulation, 2004,110(4):438-443.
[5] Frisbee JC, Falck JR, Lombard JH. Contribution of cytochrome P-450 omega-hydroxylase to altered arteriolar reactivity with high-salt diet and hypertension[J]. Am J Physiol Heart Circ Physiol,2000,278(5):H1517-H1526.
[6] Mustafa S, Vasudevan H,Yuen VG, et al. Renal expression of arachidonic acid metabolizing enzymes and RhoA/Rho kinases in fructose insulin resistant hypertensive rats[J]. Mol Cell Biochem,2010,333(1/2):203-209.
[7] Williams JM, Sharma M, Anjaiahh S, et al. Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier[J]. Am J Physiol Heart Circ Physiol, 2007,293(2):F501-F505.
[8] Nilakantan V, Maenpaa C, Jia G, et al. 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells[J]. Am J Physiol Heart Circ Physiol,2008,294(3):F562-F570.
[9] Baliga R, Zhang Z, Shah SV. Role of cytochrome P-450 in hydrogen peroxide-induced cytotoxicity to LLC-PK1 cells[J]. Kidney Int,1996,50(4):1118-1124.
[10] Shimojo N, Ishizaki T, Imaoka S, et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocininduced diabetes[J]. Biochem Pharmacol,1993,46(4):621-628.
[11] Barnett CR, Gibson GG, Wolf CR, et al. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes[J]. Biochemical J,1990,268(3):765-769.
[12] Barnett CR, Rudd S, Flatt PR, et al. Sex differences in the diabetes induced modulation of rat hepatic cytochrome P450 proteins[J]. Biochemical J,1993,45(2):313-319.
[13] Shimojo N, Ishizaki T, Imaoka S, et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozotocin-induced diabetes[J]. Biochemical J, 1993,46(4):621-628.
[14] Eid AA, Gorin Y, Fagg BM, et al.Mechanisms of podocyte injury in diabetes:role of cytochrome P450 and NADPH oxidases[J].Diatetes, 2009, 58(5):1201-1211.
[15] John Q, Chen YJ. Role of COX-2 in the enhanced vasoconstrictor effect of arachidonic acid in the diabetic rat kidney[J]. Hypertension,2003,42(4):837-843.
[16] Luo P, Zhou Y, Chang HH, et al. Glomerular 20-HETE, EETs, and TGF-β₁ in diabetic nephropathy[J]. Am J Physiol Renal Physiol,2009,65(3):F556-F563.
[17] McCarthy ET, Sharma R, Sharma M. Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier[J]. Kidney Int,2005,67(1):152-156.
[18] Natarajan R, Reddy MA. HETEs/EETs in renal glomerular and epithelial cell functions[J]. Curr Opin Pharmacol,2003,3(2):198-203.
[19] Bao Y.20-Hydroxyeicosatetraenoic acid induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways[J]. J Cardiovasc Pharmacol,2011,57(3):294-301.
[20] Zeng Q, Han Y, Bao Y.20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type Ca²⁺ channel via a PKC-dependent mechanism in cardiomyocytes[J]. Am J Physiol Heart Circ Physiol,2010,299(4):H1109-1117.
[21] Yousif MH, Benter IF, Roman RJ. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury[J]. Auto Autacoid Pharmacol,2009,29(1/2):33-41.
[22] Wang ZL, Yadav AS, Leskova W, et al. Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics[J]. Exp Eye Res,2011,93(1):108-113.
[23] Yousif MH, Benter IF. Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats[J]. Vascul Pharmacol,2007,47(5/6):281-287.